GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: compound 10b [PMID: 20138513] | GS-9441 [3] | KM-023 | KM023
                                 
                                                         
                            
                            
                            
                                 
                                
                                ainuovirine is an approved drug 
                                                        
                                                    
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: Ainuovirine (KM-023) is a non-nucleoside reverse-transcriptase inhibitor (NNRTI) class antiretroviral that is intended to treat human immunodeficiency virus (HIV) type 1 infection [1-2].
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| No information available. | 
Summary of Clinical Use ![]()  | 
                                                        
| The Chinese drug regulator (NMPA) approved the triple combination of ainuovirine, lamivudine and tenofovir (ANV) as an HIV anti-retroviral therapy in September 2024. | 
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References | 
| NCT05420246 | Efficacy and Safety of Ainuovirine Treating With AIDS Patients | Observational | Guangzhou 8th People's Hospital | ||
| NCT01348516 | Single Ascending Dose (SAD)/Multiple Ascending Dose(MAD) Safety/Pharmacokinetic (PK) Study of KM-023 | Phase 1 Interventional | Kainos Medicine Inc. | 1 | |